OBJECTIVES This study aimed to compare whether reduced heart rate (HR) or higher beta-blocker (BB) dose affected outcomes to a greater extent in the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial population.
which suggests that BB therapy should be titrated to moderate to high doses (3) .
Recent data have shown that heart rate (HR) is an important modifiable factor in reducing mortality in HF patients (4, 5) . Although HR lowering is an important effect of BBs, the prognostic benefits are not entirely related to reducing HR (1) . In an analysis from the COMET (Carvedilol or Metoprolol European Trial), the investigators demonstrated that both the HR achieved during BB therapy and BB dose were independently associated with outcomes (6); however, studies have shown a survival benefit based on HR lowering alone rather than BB dose achieved (7, 8) .
Furthermore, in a large randomized trial of the drug ivabradine, a selective HR-lowering agent, clinical outcomes were significantly improved compared with placebo (9) .
The HF-ACTION trial was the largest trial to date to test the effects of exercise training versus usual care in HF patients with moderate to severe left ventricular systolic dysfunction (10) . We aimed to examine the relationship between baseline BB dose, baseline HR, and outcomes in the HF-ACTION study population, hypothesizing that titrating patients to higher BB doses versus lowering HR may confer a greater benefit on cardiovascular outcomes.
METHODS
The HF-ACTION trial design and outcomes have been described previously (10, 11) . Briefly, the study was a multicenter, randomized controlled trial testing the long-term safety and efficacy of aerobic exercise training plus evidence-based medical therapy versus evidence-based medical therapy alone in medically stable outpatients with left ventricular systolic dysfunction (LVEF <35%) and New York Heart Association (NYHA) functional class II to IV HF. Adult subjects receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and betaadrenergic blockade for $6 weeks (unless there was a documented rationale for variation) were eligible.
The primary endpoint was the composite of death or all-cause hospitalization. Patients were randomly assigned to usual care alone or usual care plus exercise training, which consisted of a prescription of supervised aerobic exercise training at 60% to 70% of HR reserve 3 times per week, followed by home-based training at the same intensity 5 times per week, totaling 36 sessions. Randomization was stratified by center and HF pathogenesis. Participants were followed up for a median of 2.5 years.
DATA CONSIDERATIONS AND OUTCOME MEASURES. The relationship between all-cause death/hospitalization and BB dose/HR groups is shown in Figure 1 , and the clinical outcomes are shown in Table 2 . There was a significant inverse relationship between either BB dose (higher was better) or HR (lower was better) and all-cause death or hospitalization in unadjusted analysis; however, after adjust- Table 1 ).
Only BB dose was significant for improved outcomes on mortality in unadjusted analysis regardless of HR (Figure 2 ), but not after multivariable Values are median (interquartile range) or %.
6MWT ¼ 6-min walk test; BMI ¼ body mass index; BUN ¼ blood urea nitrogen; CPX ¼ cardiopulmonary exercise; HF ¼ heart failure; HR ¼ heart rate; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart Association; SBP ¼ systolic blood pressure; VO2 ¼ peak oxygen uptake. Estimated risk of death or hospitalization by discrete groups (high BB dose/high HR; high BB dose/low HR; low BB dose/high HR; low BB dose/low HR). BB ¼ beta-blocker; HR ¼ heart rate. Fiuzat et al.
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Heart Rate vs. Beta-Blocker Dose and Outcomes From the HF-ACTION Trial With regard to biomarker changes, there did not appear to be any statistically significant difference in changes in N-terminal pro-brain natriuretic peptide (NT-proBNP) between the groups, although there did appear to be a greater absolute change in the higherdose groups ( Table 3) . It is likely the numbers were too small to detect a statistical difference. Finally, we have previously shown no increased risk of bradycardia with higher doses of BB in this cohort (3) .
DISCUSSION
There are several important findings from this study. This study found an association between higher doses of beta-blockade and an improvement in the primary composite endpoint of all-cause death/ hospitalization, regardless of baseline HR being high Estimated risk of death by discrete groups (high BB dose/high HR; high BB dose/low HR; low BB dose/high HR; low BB dose/low HR).
BB ¼ beta-blocker; HR ¼ heart rate. Fiuzat et al. Fiuzat et al. Heart Rate vs. Beta-Blocker Dose and Outcomes From the HF-ACTION Trial
